Nonmyeloablative allogeneic bone marrow transplantation of a child with systemic autoimmune disease and lung vasculitis

Immunologic Research

Volumn 41, Issue 1, 2008, Pages 26-33

  Jones, Olcay Y ^a   Cahill, Richard A ^a  

^a JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOIMMUNE DISEASE; CASE REPORT; FEMALE; FOLLOW UP; HUMAN; LUNG BIOPSY; PRIORITY JOURNAL; PULMONARY VASCULITIS; REVIEW; SCHOOL CHILD; SYSTEMIC DISEASE; TREATMENT INDICATION; TREATMENT OUTCOME;

ADOLESCENT; AUTOIMMUNE DISEASES; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; HUMANS; LUNG; LUNG DISEASES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VASCULITIS;

EID: 46249119936     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-007-0015-1     Document Type: Review

References (39)

1. Jones OY, Cahill RA, Good RA. Nonmyeloablative allogeneic bone marrow transplantation for treatment of childhood overlap syndrome and small vessel vasculitis. Bone Marrow Transplant 2004;33:1061-3
2. Ishida T, Inaba M, Hisha H, Sugiura K, Adachi Y, Nagata N, et al. Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. Complete prevention of recurrence of autoimmune diseases in MRL/MP-lpr/lpr mice by transplantation of bone marrow plus bones (stromal cells) from the same donor. J Immunol 1994;152:3119-27
3. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989;169:493-502
4. Ikehara S, Yasumizu R, Inaba M, Izui S, Hayakawa K, KenIchu S, et al. Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 1989;86:3306-10
5. Chamarthy LM, de la Morena M, Lacson A, Cawkwell G, Good RA. Pulmonary vasculitis presenting as atypical asthma. Ann Allergy Asthma Immunol 2000;84:495-8
6. Cahill RA, Jones OY, Klemperer M, Steele A, Mueller TO, El-Badri N, et al. Replacement of recipient stromal/mesenchymal cells after bone marrow transplantation using bone fragments and cultured osteoblast-like cells. Biol Blood Marrow Transplant 2004;10:709-17
7. Slavin S, Nagler A, Varadi G, Or R. Graft vs autoimmunity following allogeneic nonmyeloablative blood stem cell transplantationin a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 2000;28:853-7
8. Chakrabarti S, Handa SK, Bryon RJ, Griffiths MJ, Milligan DW. Will mixed chimerism cure autoimmune diseasesafter a nonmyeloablative stem cell transplant? Transplantation 2001;72:340-2
9. Oyama Y, Papadopoulos EB, Miranda M, Traynor AE, Burt RK. Allogeneic stem cell transplantation for Evans syndrome. Bone Marrow Transplant 2001;28:903-5
10. Marmont AM, Gualandi F, van Lint MT, Bacigalupo A. Refractory Evans' syndrome treated with allogeneic SCT followed by DLI. Demostration of a graft-versus-autoimmunity effect. Bone Marrow Transplant 2003;31:399-402
11. Burt RK, Oyama Y, Verda L, Quigley K, Brush M, Yaung K, et al. Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism. Arhtritis Rheum 2004;50(8):2466-70
12. Morton JI, Siegel BV. Transplantation of autoimmune potential. I. Development of antinuclear antibodies in H-2 histocompatible recipients of bone marrow from New Zealand Black mice. Proc Natl Acad Sci USA 1974;71:2162-5
13. Morton JI, Siegel BV. Transplantation of autoimmune potential. IV. Reversal of the NZB autoimmune syndrome by bone marrow transplantation. Transplantation 1979;27:133-40
14. Eisenberg RA, Izui S, McConahey PJ, Hang L, Peters CJ, Theofilopoulos AN, et al. Male determined accelerated autoimmune disease in BXSB mice: transfer by bone marrow and spleen cells. J Immunol 1980;125:1032-6
15. Jyonouchi H, Kincade PW, Good RA, Fernandes G. Reciprocal transfer of abnormalities in clonable B lymphocytes and myeloid progenitors between NZB and DBA/2 mice. J Immunol 1981;127:1232-5
16. Himeno K, Good RA. Marrow transplantation from tolerant donors to treat and prevent autoimmune diseases in BXSB mice. Proc Natl Acad Sci USA 1988;85:2235-9
17. Ikehara S, Good RA, Nakamura T, Sekita K, Inoue S, Oo MM, et al. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci USA 1985;82:2483-7
18. Wang BY, Cherry, El-Badri NS, Good RA. Prevention of development of autoimmune disease in BXSB mice by mixed bone marrow transplantation. Proc Natl Acad Sci USA 1997;94:12065-9
19. Wang B, Yamamoto Y, El-Badri NS, Good RA. Effective treatment of autoimmune disease and progressive renal disease by mixed bone-marrow transplantation that establishes a stable mixed chimerism in BXSB recipient mice. Proc Natl Acad Sci USA 1999;96:3012-6
20. Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Sachs DH. Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med 1985;162:231-44
21. Jones OY, Steele A, Jones JM, Marikar Y, Chang Y, Feliz A, et al. Nonmyeloablative bone marrow transplantation of BXSB lupus mice using fully matched allogeneic donor cells from green fluorescent protein transgenic mice. J Immunol 2004;172:5415-9
22. Seung E, Iwakoshi N, Woda BA, Markees TG, Mordes JP, Rossini AA, et al. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody:absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood 2000;95:2175-82
23. Wu T, Levay-Young B, Heuss N, Sozen H, Kirchhof N, Sutherland DE, et al. Inducing tolerance to MHC-matched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and one marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy. Transplantation 2002;74:22-7
24. Leykin I, Nikolic B, Sykes M. mixed bone marrow chimerism as a treatment for autoimmune diabetes. Transplant Proc 2001;33:120
25. Hashimoto F, Sugiura K, Inoue K, Ikehara S. Major histocompatibility complex restriction between hematopoietic stem cells and stromal cells in vivo. Blood 1997;89:49-54
26. Imasawa T, Utsunomiya Y, Kawamura T, Zhong Y, Nagasawa R, Okabe M, et al. The potential of bone marrow derived cells to differentiate to glomerular mesengial cells. J Am Soc Nephrol 2001;12:1401-9
27. Yamada M, Kubo H, Kobayashi S, Ishizawa K, Numasaki M, Ueda S, et al. Bone marrow-derived progenitor cells are important for lung repair after lipopolysaccaride-induced lung injury. J Immunol 2004;172:1266-72
28. El-Badri NS, Maheshwari A, Sanberg PR. Mesenchymal stem cells in autoimmune diseases. Stem Cells Dev 2004;13:463-72
29. Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000;18:307-16
30. Whyte MP, Kurtzberg J, McAlister WH, Mumm S, Podgornik MN, Coburn SP, et al. Marrow cell transplantation for infantile hypophosphatasia. J Bone Mineral Res 2003;18:624-36
31. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005;90(4):516-25
32. Uccelli A, Zappia E, Benvenuto F, Frassoni F, Mancardi G. Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. Expert Opin Biol Ther 2006;6:17-22
33. Manilay JO, Pearson DA, Sergio JJ, Swenson KG, Sykes M. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation 1998;66:96-102
34. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal cells modulate B-cell functions. Blood 2006;107:367-72
35. Griffith LM, Pavletic SZ, Tyndall A, Bredeson CN, Bowen JD, Childs RW, et al. Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a national institute of allergy and infectious diseases and national cancer institute-sponsored international workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant 2005;11:862-70
36. Griffith LM, Pavletic SZ, Tyndall A, Gratwobl A, Furst DE, Forman SJ, et al. Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases: a workshop accompanying cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapy-sponsored by the Bernie Marcus Foundation and the City of Hope National Medical Center, in collaboration with NIAID, NCI, EULAR, and EBMT; Newport Beach, California; October 7, 2005. Biol Blood Bone Marrow Transplant 2006 (in press)
37. Jones OY, Pavletic SZ. Stem cell transplant in autoimmune diseases, a decade long clinical experience - a promising new chapter. Pediatr Rheumatol Online Journal 2006;4
38. Morita H, Sugiura K, Inaba M, Jin T, Ishikawa J, Lian Z, et al. A strategy for organ allografts without using immunosuppressants or irradiation. Proc Natl Acad Sci USA 1998;95:6947-52
39. Good RA. Cellular immunology in a historical perspective. Immunol Rev 2002;185:136-58